



Date: 12/11/2019

To,
The **Board of Directors**,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period ended **30th September, 2019** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act,2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES
Chartered Accountants

CA MAYANK SANCHETI
PARTNER
M No: 170863
FRN:129406W
Date: 12/11/2019
Place: Ahmedabad
UDIN: 19170863AAAAGC3056

16		Total Profit / (Loss) for the period	12.70	12.20	8.33	24.90	16.22	35.16
17		Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00	0.00
18		Total Comprehensive Income for the Period	12.70	12.20	8.33	24.90	16.22	35.16
19		Total profit or loss attributable to						
		Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
		Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
20		Total comprehensive income for the period attributable to						
		Comprehensive Income for the period attributable to the owners of parent	0.00	0.00	0.00	0.00	0.00	0.00
		Total comprehensive Income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
21		Details of Equity Share Capital						
		Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03	299.03
		Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
22		Details of Debt Securities						
		Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00	0.00
		Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00	0.00
23		Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
24		Debt Redemption Reserve	0.00	0.00	0.00	0.00	0.00	0.00
25		Earnings Per Share						
	(i)	Earnings Per Share for continuing operations						
		Basic Earnings / (Loss) per share from continuing operations	0.42	0.41	0.28	0.83	0.54	1.18
		Diluted Earnings / (Loss) per share from continuing operations	0.42	0.41	0.28	0.83	0.54	1.18
	(ii)	Earnings Per Share for discontinued operations						
		Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
		Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	(iii)	Earnings per Equity Share						
		Basic Earnings / (Loss) per share from continuing and discontinued operations	0.42	0.41	0.28	0.83	0.54	1.18
		Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.42	0.41	0.28	0.83	0.54	1.18
26		Debt Equity Ratio	--	--	--	--	--	--
27		Debt Service Coverage Ratio	--	--	--	--	--	--
28		Interest Service Coverage Ratio	--	--	--	--	--	--

As per financial statements



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 12, 2019.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2019 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

Place	Ahmedabad	JAGDISH AGRAWAL
Date	12-Nov-19	MANAGING DIRECTOR DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 9228016100

Statement of Assets and Liabilities

Amount in ₹

Particulars	Half Year Ended	Previous Year Ended
	6 Months Ended	12 Months Ended
	Unaudited	Audited
	30-Sep-19	31-Mar-19
ASSETS		
1 Non-current assets		
Property, plant and equipment	12298459	12998979
Capital work-in-progress		
Investment property		
Goodwill		
Other intangible assets		
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
Non-current financial assets	12298459	12998979
Non-current investments	1592254	1592254
Trade receivables, non-current		
Loans, non-current		
Other non-current financial assets	506200	506200
Total Non-current financial assets	2098454	2098454
Deferred tax assets (net)		
Other non-current assets		
Total Non-current Assets	14396913	15097433
2 Current assets		
Inventories	10161406	7387752
Current financial assets		
Current investments	41070956	38787641
Trade receivables, current	22196105	11803412
Cash and cash equivalents	28964	239078
Bank balance other than cash and cash equivalent	9114831	9871972
Loans, current	485376	244600
Other current financial assets	1650000	1000000
Total current financial assets	74546232	61946703
Current tax assets (net)		
Other current assets		
Total Current Assets		
3 Non-current assets classified as held for sale		
4 Regulatory deferral account debit balances and related deferred tax Assets		
TOTAL ASSETS	99104551	84431888

For Director approval



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	29903000	29903000
	Other equity	36726332	34236519
	Total Equity attributable to owners of Parent	66629332	64139519
	Non controlling interest		
	Total Equity	66629332	64139519
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	827712	1224637
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	827712	1224637
	Provisions, non-current		
	Deferred tax liabilities (net)	556394	556394
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	556394	556394
	Current liabilities		
	Current financial liabilities		
	Borrowing, current		45052
	Trade payables, current	25599706	13785833
	Other current financial liabilities	793850	776777
	Total current financial liabilities	26393556	14607662
	Other current liabilities	2463558	2298018
	Provisions, current	328789	455658
	Current tax liabilities (Net)	1905210	1150000
	Deferred government grants, Current		
	Total current liabilities	4697557	3903676
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities		
	Total Equity and Liabilities	99104551	84431888

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

Place	Ahmedabad	JAGDISH AGRAWAL
Date	12-Nov-19	MANAGING DIRECTOR
		DIN: 01031687